Editorial: Community Series in Tumor Microenvironment and Metabolic Reprogramming in Cancer: Volume II
-
By
-
Sang, Yaodong
-
Gao, Huanyu
-
Li, Jingsi
-
Raza, Asif
-
Zhu, Houjuan
-
Cui, Xiaoling
-
Wei, Yiju
-
Chen, Hao
-
Chong, Wei
-
June 3, 2026
-
Clinical Scorecard: Insights on Tumor Microenvironment and Cancer Metabolic Reprogramming: Volume II
At a Glance
| Category | Detail |
|---|
| Condition | Cancer |
| Key Mechanisms | Tumor microenvironment (TME) and metabolic reprogramming |
| Target Population | Cancer patients |
| Care Setting | Oncology |
Key Highlights
- TME plays a critical role in tumor initiation, progression, and metastasis.
- Metabolic reprogramming is a hallmark of cancer driven by the TME.
- Tumor metabolites reshape the TME and suppress antitumor immunity.
- Emerging therapeutic approaches include metabolism-targeted cancer therapies.
- Multi-omics data and spatial biology technologies are key for personalized therapy.
Guideline-Based Recommendations
Diagnosis
- Utilize multi-omics data to guide personalized therapy.
Management
- Consider metabolism-targeted therapies in cancer treatment.
Monitoring & Follow-up
- Assess tumor-immune interactions and metabolic signaling.
Risks
- Therapeutic resistance linked to metabolic reprogramming.
Patient & Prescribing Data
Patients with various types of cancer.
Active targeted delivery of therapeutic agents, such as resveratrol, shows promise.
Clinical Best Practices
- Integrate multi-omics analysis in treatment planning.
- Explore combined targeted metabolic-immune therapies.
Related Resources & Content
